The agreement includes an additional $500 million in contingent payments tied to regulatory and sales milestones. For Jazz, the move serves as a strategic expansion of its existing epilepsy franchise, building on the commercial reach of its established product, Epidiolex. ABS-1230, a novel small molecule KCNT1 inhibitor, has already demonstrated meaningful seizure reductions in early clinical trials and holds several regulatory designations, including FDA Fast Track and Rare Pediatric Disease status.

KCNT1-related epilepsy is a severe, often fatal condition affecting roughly 2,500 patients in the United States. Many children diagnosed with the disease face daily, treatment-resistant seizures that hinder basic developmental milestones like walking or speaking. The ongoing Phase 1b/2a KYRON trial for ABS-1230 is intended to serve as the registrational study for future U.S. regulatory filings. As part of the transaction, Actio Biosciences will spin out a separate entity to focus on other genetic neurological programs, including a TRPV4 inhibitor for Charcot-Marie-Tooth disease. The acquisition, approved by the boards of both companies, is expected to close by the fourth quarter of 2026.